Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Students will be learning at the College of Saint Rose campus again soon, but only in one building. There, they will learn skilled trades and technical training for jobs at GlobalFoundries, Regeneron, ...

Regeneron is the second pharma group to sign ... Those can be used for "natural history analysis, trial design, cohort formation, and data analysis," according to the partners.

Addison Shea is one of 40 finalists for the Science Talent Search finals in Washington, D.C., in March. Addison Shea couldn’t ...

In School Zone, Central trustees name new school; Clovis North seniors nab science awards; Fresno teachers not ready for goals?

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.